Get the Stockscreener App
32.59
6.89%
-2.41
After Hours:
32.64
0.05
+0.15%
Eton Pharmaceuticals Inc stock is traded at $32.59, with a volume of 522.24K.
It is down -6.89% in the last 24 hours and up +38.03% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$35.00
Open:
$35
24h Volume:
522.24K
Relative Volume:
1.26
Market Cap:
$892.72M
Revenue:
$79.95M
Net Income/Loss:
$-4.60M
P/E Ratio:
-182.37
EPS:
-0.1787
Net Cash Flow:
$10.19M
1W Performance:
+7.70%
1M Performance:
+38.03%
6M Performance:
+98.00%
1Y Performance:
+60.94%
1-Day Range:
$32.52
$35.00
1-Week Range:
$29.87
$35.66
52-Week Range:
$13.09
$35.66
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
32.59 | 958.73M | 79.95M | -4.60M | 10.19M | -0.1787 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
ETON SEC FilingsEton Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy - Insider Monkey
Eton Pharmaceuticals Inc (ETON) Shares Fall 6.9% -- GF Value Says Still Overvalued - GuruFocus
ETON (Nasdaq) Rule 144 shows RSUs and Options grants dated 2024–2026 - Stock Titan
5 Oversold Growth Stocks to Invest In Now - Insider Monkey
H.C. Wainwright reiterates Eton Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results By Investing.com - Investing.com Nigeria
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results - Investing.com
Eton Pharmaceuticals (ETON) soars 6.7%: Is further upside left in the stock? - MSN
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug By Investing.com - Investing.com South Africa
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug - Investing.com
Eton Pharmaceuticals Obtains US Commercialization Rights to Impavido - Moomoo
Eton (NASDAQ: ETON) licenses U.S. IMPAVIDO rights in rare disease push - Stock Titan
Eton Pharmaceuticals Announces U.S. Commercialization Rights for IMPAVIDO®, First FDA-Approved Oral Therapy for Leishmaniasis - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Eton Pharmaceuticals, Inc.Common Stock (NQ: ETON - The Chronicle-Journal
Price-Driven Insight from (ETON) for Rule-Based Strategy - Stock Traders Daily
H.C. Wainwright raises Eton Pharmaceuticals stock price target to $57 By Investing.com - Investing.com Canada
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2026 Earnings Call Transcript - Insider Monkey
Eton Pharmaceuticals Q1 Non-GAAP EPS, Revenue Rise - Moomoo
Eton Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Eton projects revenue to exceed $120M in 2026 as it targets a 50% adjusted EBITDA margin by 2028 - MSN
Eton Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
MSN Money - MSN
Eton Pharmaceuticals, Inc. (ETON) misses Q1 earnings estimates - MSN
ETON: Record Q1 sales and new product launches drive raised 2026 revenue guidance above $120 million - TradingView
Eton Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Eton Pharmaceuticals Q1 2026 revenue beats, EPS misses - Investing.com
Eton Pharmaceuticals earnings missed by $0.14, revenue topped estimates - Investing.com
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates - Yahoo Finance
Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call - Benzinga
ETON PHARMACEUTICALS ($ETON) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Eton Pharmaceuticals (ETON) swings to Q1 2026 profit as rare disease sales grow - Stock Titan
Surging sales turn Eton Pharmaceuticals (NASDAQ: ETON) profitable in Q1 2026 - Stock Titan
Earnings Flash (ETON) Eton Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.14 per Share, vs. FactSet Est of $0.14 - marketscreener.com
Earnings Flash (ETON) Eton Pharmaceuticals, Inc. Reports Q1 Revenue $24.3M, Vs. FactSet Est of $22.3M - Moomoo
Press Release: Eton Pharmaceuticals Reports First Quarter 2026 Financial Results - Moomoo
Does Eton Pharmaceuticals (ETON) have the potential to rally 49.25% as Wall Street analysts expect? - MSN
Eton Pharmaceuticals Q1 2026 earnings preview - MSN
Eton Pharmaceuticals raises 2026 revenue forecast after Q1 sales jump 73% and new product launches. - Pluang
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):